Covered recipient · General Payments record
AARON S FARBERG
Allopathic & Osteopathic Physicians Dermatology MOHS-Micrographic Surgery
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$419,066.13
406 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $241,686.48 | 79 |
| Consulting Fee | $136,398.08 | 44 |
| Travel and Lodging | $21,726.22 | 105 |
| Compensation for serving as faculty or as a speaker for a medical education program | $12,840.00 | 7 |
| Food and Beverage | $6,386.39 | 169 |
| Education | $28.96 | 2 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| UCB, Inc. | $58,764.07 | 68 |
| Janssen Biotech, Inc. | $51,031.82 | 47 |
| Regeneron Healthcare Solutions, Inc. | $50,182.99 | 34 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $48,631.93 | 27 |
| Galderma Laboratories, L.P. | $47,030.32 | 36 |
| Incyte Corporation | $29,590.57 | 33 |
| PFIZER INC. | $28,547.27 | 18 |
| Novartis Pharmaceuticals Corporation | $22,543.78 | 20 |
| Botanix SB Inc | $18,881.48 | 14 |
| Amgen Inc. | $16,850.55 | 20 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $14,976.80 | 6 |
| Almirall LLC | $11,129.02 | 11 |
| ABBVIE INC. | $6,961.17 | 14 |
| Eli Lilly and Company | $6,927.52 | 3 |
| Boehringer Ingelheim International GmbH | $2,906.88 | 2 |
| Janssen Scientific Affairs, LLC | $2,887.50 | 1 |
| LEO Pharma Inc. | $631.34 | 32 |
| GENZYME CORPORATION | $185.61 | 6 |
| E.R. Squibb & Sons, L.L.C. | $158.53 | 2 |
| Boehringer Ingelheim Pharma GmbH & Co.KG | $50.29 | 1 |
| Biofrontera Inc. | $44.36 | 2 |
| STRATA Skin Sciences, Inc. | $43.58 | 4 |
| Arcutis Biotherapeutics, Inc. | $35.63 | 2 |
| Kerecis Limited | $31.12 | 1 |
| BioWound Solutions, Inc. | $25.01 | 1 |
| MIMEDX Group, Inc. | $16.99 | 1 |
Page 4 of 9; records 151–200 of 406 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
AARON S FARBERG
NPI 1134480239 · CMS profile ID 1392313
Allopathic & Osteopathic Physicians / Dermatology / MOHS-Micrographic Surgery
ROCKWALL, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 4 of 9; records 151–200 of 406 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1134480239?year=2025&recipient=provider&page=4#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- AARON S FARBERG, NPI 1134480239, CMS profile ID 1392313. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 9; records 151–200 of 406 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1134480239?year=2025&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). AARON S FARBERG, NPI 1134480239, CMS profile ID 1392313. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 9; records 151–200 of 406 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1134480239?year=2025&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- AARON S FARBERG, NPI 1134480239, CMS profile ID 1392313, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 9; records 151–200 of 406 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1134480239?year=2025&recipient=provider&page=4#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
406 matching records · $419,066.13 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 151–200 of 406.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Regeneron Healthcare Solutions, Inc. | $23.50 | 08/26/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1212917260 | CMS |
| Galderma Laboratories, L.P. | $9.90 | 08/20/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234639634 | CMS |
| LEO Pharma Inc. | $138.44 | 08/19/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1252004204 | CMS |
| ABBVIE INC. | $12.52 | 08/18/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1201837391 | CMS |
| Novartis Pharmaceuticals Corporation | $187.51 | 08/15/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200265112 | CMS |
| Novartis Pharmaceuticals Corporation | $19.25 | 08/15/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200265114 | CMS |
| Novartis Pharmaceuticals Corporation | $7,000.00 | 08/15/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200265116 | CMS |
| Novartis Pharmaceuticals Corporation | $167.49 | 08/15/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200265118 | CMS |
| Novartis Pharmaceuticals Corporation | $568.06 | 08/15/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200265120 | CMS |
| Novartis Pharmaceuticals Corporation | $396.19 | 08/14/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200215231 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $1,500.00 | 08/12/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250962661 | CMS |
| UCB, Inc. | $25.23 | 08/12/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224416333 | CMS |
| Incyte Corporation | $4,500.00 | 08/08/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226009663 | CMS |
| Incyte Corporation | $4,875.00 | 08/08/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226011037 | CMS |
| Galderma Laboratories, L.P. | $600.00 | 08/04/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234639632 | CMS |
| LEO Pharma Inc. | $15.27 | 08/04/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1252004200 | CMS |
| LEO Pharma Inc. | $13.50 | 08/04/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1252004202 | CMS |
| Regeneron Healthcare Solutions, Inc. | $1.08 | 07/31/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1212917256 | CMS |
| Regeneron Healthcare Solutions, Inc. | $31.35 | 07/31/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1212917258 | CMS |
| E.R. Squibb & Sons, L.L.C. | $9.28 | 07/30/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184583939 | CMS |
| PFIZER INC. | $5.20 | 07/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1230109315 | CMS |
| Janssen Biotech, Inc. | $1,275.00 | 07/26/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175119396 | CMS |
| BioWound Solutions, Inc. | $25.01 | 07/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1182971683 | CMS |
| Galderma Laboratories, L.P. | $2,600.00 | 07/23/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234639630 | CMS |
| Amgen Inc. | $15.45 | 07/22/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228266063 | CMS |
| PFIZER INC. | $8.69 | 07/22/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1231657045 | CMS |
| Regeneron Healthcare Solutions, Inc. | $1,010.50 | 07/22/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1212917254 | CMS |
| STRATA Skin Sciences, Inc. | $2.65 | 07/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1253014180 | CMS |
| Almirall LLC | $11.27 | 07/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1243877340 | CMS |
| LEO Pharma Inc. | $16.03 | 07/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1252004198 | CMS |
| Galderma Laboratories, L.P. | $2,250.00 | 07/02/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234639628 | CMS |
| Incyte Corporation | $3,000.00 | 07/02/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226009947 | CMS |
| PFIZER INC. | $1,125.00 | 07/01/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1231110285 | CMS |
| Regeneron Healthcare Solutions, Inc. | $65.80 | 07/01/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1212917252 | CMS |
| PFIZER INC. | $7.64 | 06/30/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1231577138 | CMS |
| Almirall LLC | $1,275.00 | 06/27/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1243877420 | CMS |
| Incyte Corporation | $97.43 | 06/27/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226140892 | CMS |
| Regeneron Healthcare Solutions, Inc. | $1,290.00 | 06/27/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1212917244 | CMS |
| Regeneron Healthcare Solutions, Inc. | $1,935.00 | 06/27/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1212917246 | CMS |
| Regeneron Healthcare Solutions, Inc. | $1,935.00 | 06/27/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1212917248 | CMS |
| Regeneron Healthcare Solutions, Inc. | $2,580.00 | 06/27/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1212917250 | CMS |
| Incyte Corporation | $6.78 | 06/26/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226011035 | CMS |
| Incyte Corporation | $17.00 | 06/26/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226011047 | CMS |
| Incyte Corporation | $5.00 | 06/26/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226140804 | CMS |
| Incyte Corporation | $15.72 | 06/26/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226140815 | CMS |
| Incyte Corporation | $120.13 | 06/26/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226140845 | CMS |
| Incyte Corporation | $20.95 | 06/26/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226144477 | CMS |
| Incyte Corporation | $1,017.96 | 06/25/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226011031 | CMS |
| Incyte Corporation | $5.29 | 06/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226011033 | CMS |
| Incyte Corporation | $368.50 | 06/25/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226140801 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $1,260.80 | 2 |
| PY2025 | Principal investigator | $257,245.52 | 53 |
| PY2024 | Principal investigator | $63,004.00 | 20 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
55 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,777.50 | 12/22/2025 | Non-covered Recipient Entity Reveal Research Institute Pllc | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226082858 |
| Principal investigator 1 | Incyte Corporation | $3,038.90 | 12/19/2025 | Non-covered Recipient Entity REVEAL RESEARCH INSTITUTE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240582231 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,278.32 | 12/19/2025 | Non-covered Recipient Entity REVEAL RESEARCH INSTITUTE | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184279324 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $51,063.75 | 12/19/2025 | Non-covered Recipient Entity REVEAL RESEARCH INSTITUTE | TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223290008 |
| Principal investigator 1 | Incyte Corporation | $1,968.30 | 12/04/2025 | Non-covered Recipient Entity REVEAL RESEARCH INSTITUTE | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240582162 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,559.45 | 12/04/2025 | Non-covered Recipient Entity REVEAL RESEARCH INSTITUTE | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184269511 |
| Principal investigator 1 | Incyte Corporation | $1,732.40 | 11/26/2025 | Non-covered Recipient Entity REVEAL RESEARCH INSTITUTE | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240582265 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,386.70 | 11/24/2025 | Non-covered Recipient Entity Reveal Research Institute Pllc | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226082827 |
| Principal investigator 1 | Incyte Corporation | $3,915.90 | 11/20/2025 | Non-covered Recipient Entity REVEAL RESEARCH INSTITUTE | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240582261 |
| Principal investigator 1 | Incyte Corporation | $1,533.10 | 11/19/2025 | Non-covered Recipient Entity REVEAL RESEARCH INSTITUTE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240582167 |
| Principal investigator 1 | Incyte Corporation | $1,824.00 | 11/19/2025 | Non-covered Recipient Entity REVEAL RESEARCH INSTITUTE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240582171 |
| Principal investigator 1 | Incyte Corporation | $1,824.00 | 11/19/2025 | Non-covered Recipient Entity REVEAL RESEARCH INSTITUTE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240582175 |
| Principal investigator 1 | Incyte Corporation | $2,748.00 | 11/19/2025 | Non-covered Recipient Entity REVEAL RESEARCH INSTITUTE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240582180 |
| Principal investigator 1 | Incyte Corporation | $2,748.00 | 11/19/2025 | Non-covered Recipient Entity REVEAL RESEARCH INSTITUTE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240582184 |
| Principal investigator 1 | Incyte Corporation | $2,748.00 | 11/19/2025 | Non-covered Recipient Entity REVEAL RESEARCH INSTITUTE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240582188 |
| Principal investigator 1 | Incyte Corporation | $2,748.00 | 11/19/2025 | Non-covered Recipient Entity REVEAL RESEARCH INSTITUTE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240582191 |
| Principal investigator 1 | Incyte Corporation | $2,748.00 | 11/19/2025 | Non-covered Recipient Entity REVEAL RESEARCH INSTITUTE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240582194 |
| Principal investigator 1 | Incyte Corporation | $62.00 | 11/19/2025 | Non-covered Recipient Entity REVEAL RESEARCH INSTITUTE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240582198 |
| Principal investigator 1 | Incyte Corporation | $62.00 | 11/19/2025 | Non-covered Recipient Entity REVEAL RESEARCH INSTITUTE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240582203 |
| Principal investigator 1 | Incyte Corporation | $62.00 | 11/19/2025 | Non-covered Recipient Entity REVEAL RESEARCH INSTITUTE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240582207 |
| Principal investigator 1 | Incyte Corporation | $62.00 | 11/19/2025 | Non-covered Recipient Entity REVEAL RESEARCH INSTITUTE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240582211 |
| Principal investigator 1 | Incyte Corporation | $1,917.00 | 11/19/2025 | Non-covered Recipient Entity REVEAL RESEARCH INSTITUTE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240582215 |
| Principal investigator 1 | Incyte Corporation | $1,987.00 | 11/19/2025 | Non-covered Recipient Entity REVEAL RESEARCH INSTITUTE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240582220 |
| Principal investigator 1 | Incyte Corporation | $1,987.00 | 11/19/2025 | Non-covered Recipient Entity REVEAL RESEARCH INSTITUTE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240582223 |
| Principal investigator 1 | Incyte Corporation | $1,987.00 | 11/19/2025 | Non-covered Recipient Entity REVEAL RESEARCH INSTITUTE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240582227 |
| Principal investigator 1 | Incyte Corporation | $101.00 | 11/19/2025 | Non-covered Recipient Entity REVEAL RESEARCH INSTITUTE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240582234 |
| Principal investigator 1 | Incyte Corporation | $101.00 | 11/19/2025 | Non-covered Recipient Entity REVEAL RESEARCH INSTITUTE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240582238 |
| Principal investigator 1 | Incyte Corporation | $101.00 | 11/19/2025 | Non-covered Recipient Entity REVEAL RESEARCH INSTITUTE | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240582242 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $10,580.98 | 11/10/2025 | Non-covered Recipient Entity DERMATOLOGY TREATMENT AND RESEARCH CENTER | A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista | No dispute reported | 06/30/2026 | 1190304877 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $7,755.75 | 11/03/2025 | Non-covered Recipient Entity REVEAL RESEARCH INSTITUTE | TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223287881 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,722.91 | 10/29/2025 | Non-covered Recipient Entity REVEAL RESEARCH INSTITUTE | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184253801 |
| Principal investigator 1 | Incyte Corporation | $1,968.30 | 10/28/2025 | Non-covered Recipient Entity REVEAL RESEARCH INSTITUTE | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240582253 |
| Principal investigator 1 | Incyte Corporation | $1,854.90 | 10/23/2025 | Non-covered Recipient Entity REVEAL RESEARCH INSTITUTE | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240582249 |
| Principal investigator 1 | Incyte Corporation | $4,506.00 | 10/16/2025 | Non-covered Recipient Entity REVEAL RESEARCH INSTITUTE | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240582258 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,741.30 | 09/15/2025 | Non-covered Recipient Entity Reveal Research Institute Pllc | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226082781 |
| Principal investigator 1 | Incyte Corporation | $5,884.20 | 09/04/2025 | Non-covered Recipient Entity REVEAL RESEARCH INSTITUTE | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240582246 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $886.38 | 09/04/2025 | Non-covered Recipient Entity REVEAL RESEARCH INSTITUTE | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184235331 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,550.57 | 08/14/2025 | Non-covered Recipient Entity REVEAL RESEARCH INSTITUTE | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184228631 |
| Recipient | Eli Lilly and Company | $1,230.00 | 08/08/2025 | Covered Recipient Physician | A PHASE 4, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH ATOPIC DERMATITIS WITH LIMITED BODY SURFACE AREA INVOLVEMENT AND HIGH ITCH BURDEN (ADSOLVE) | No dispute reported | 06/30/2026 | 1187873293 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,265.31 | 07/31/2025 | Non-covered Recipient Entity REVEAL RESEARCH INSTITUTE | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184223002 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $7,027.10 | 07/22/2025 | Non-covered Recipient Entity REVEAL RESEARCH INSTITUTE | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184217963 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $6,342.30 | 07/14/2025 | Non-covered Recipient Entity Reveal Research Institute Pllc | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226082726 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $17,500.00 | 07/11/2025 | Non-covered Recipient Entity REVEAL RESEARCH INSTITUTE | TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223282592 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,815.00 | 06/09/2025 | Non-covered Recipient Entity Reveal Research Institute Pllc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment | No dispute reported | 06/30/2026 | 1226082679 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $10,917.90 | 05/27/2025 | Non-covered Recipient Entity Reveal Research Institute Pllc | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226082673 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,576.00 | 03/19/2025 | Non-covered Recipient Entity REVEAL RESEARCH INSTITUTE | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184174360 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $10,500.00 | 03/19/2025 | Non-covered Recipient Entity REVEAL RESEARCH INSTITUTE | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184174362 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $10,118.00 | 03/19/2025 | Non-covered Recipient Entity REVEAL RESEARCH INSTITUTE | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184174364 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $30.80 | 03/14/2025 | Covered Recipient Physician | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184117435 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,328.00 | 03/10/2025 | Non-covered Recipient Entity Reveal Research Institute Pllc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment | No dispute reported | 06/30/2026 | 1226082613 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,800.00 | 02/24/2025 | Non-covered Recipient Entity Reveal Research Institute Pllc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment | No dispute reported | 06/30/2026 | 1226082621 |
| Principal investigator 1 | Incyte Corporation | $1,500.00 | 01/29/2025 | Non-covered Recipient Entity REVEAL RESEARCH INSTITUTE | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240582269 |
| Principal investigator 1 | Incyte Corporation | $1,500.00 | 01/29/2025 | Non-covered Recipient Entity REVEAL RESEARCH INSTITUTE | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240582274 |
| Principal investigator 1 | Incyte Corporation | $7,500.00 | 01/29/2025 | Non-covered Recipient Entity REVEAL RESEARCH INSTITUTE | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240582278 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $27,033.30 | 01/21/2025 | Non-covered Recipient Entity Reveal Research Institute Pllc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment | No dispute reported | 06/30/2026 | 1226082593 |